Fig. 4

Whole blood and PBMC cytokine release and T-cell activation. A Cytokine release from whole blood induced by NILK-2301 following 24 h of incubation. MEDI-565 BiTE and cetuximab (Cetux) were used as control antibodies. Each dot represents the value measured for a given antibody and for a given donor. Measurements obtained with a given donor are pictured with the same color. No significant non-target cell associated cytokine release as compared to control (PBS) was observed for NILK-2301. B T-cell activation and cytokine release from healthy donor PBMCs induced by NILK-2301 after 48 h of incubation. Muromonab and cetuximab (Cetux) were used as control antibodies. As for whole blood, no significant non-target cell mediated T-cell activation or cytokine release as compared to control (PBS) or T-cell activation was observed for NILK-2301. Measurements obtained with a given donor are pictured with the same color. Asterisks denote significance to the level of *P < 0.05, **P < 0.01, ***P = 0.001, and ****P < 0.0001. ns, not significant